Institutional Core Labs
- iLabs
- Bioanalytics & Single-Cell
- Biospecimen and Translational Genomics
- Flow Cytometry
- Mass Spectometry
- Optical Imaging
- Structural Biology (NMR)
- Structural Biology (X-Ray Crystallography)
Find a Researcher
Research by School
Software Training & Cyberinfrastructure
Additional Resources
Infectious Disease
UT Health San Antonio examines infectious diseases of regional and national significance, including hepatitis, HIV, multidrug resistant bacteria, clostridium difficile and MRSA infections.
Infectious disease expert Sunil Ahuja, M.D. earned the prestigious MERIT Award an honor bestowed on less than five percent of NIH-funded researchers.
Dr. Thomas Patterson led one of the largest study sites for the remdesivir COVID-19 clinical trial in the world.
Join us in the fight against COVID-19! The Novavax clinical trial to evaluate an investigational vaccine is enrolling participants. Take action today...volunteer and play a role in finding a cure.
Find
UT Health San Antonio partners with the Vaccine Development Center of San Antonio which fosters research collaborations to promote excellence in vaccine development.
Additional Highlights
-
Listen up! Infectious disease experts share COVID knowledge through podcasts
UT Health San Antonio infectious disease physicians are offering a podcast series called “COVID Minutes” for anyone who would like to learn more about the pandemic including health care workers, who can earn continuing medical education credits at no cost.
Read the full story in Impact -
The task of testing: Pathology lab team goes ‘above and beyond’ to support community
Being both on the frontlines and behind the scenes, the work done in the UT Health San Antonio pathology labs has been and continues to be crucial in the response to COVID-19 in the community. With 20,145 samples processed to date, the technologists in the pathology labs are “truly in the trenches” in the fight against COVID-19, said Marjorie David, MD, MS, director of the molecular diagnostic laboratory in the Department of Pathology and Laboratory Medicine.
Read the full story in Impact -
FDA approves remdesivir for COVID-19 patients
The U.S. Food and Drug Administration announced Oct. 22 that the drug remdesivir (Veklury) is the first approved treatment for COVID-19. The antiviral medication has been tested in study sites internationally since February, including a study site led by UT Health San Antonio with its clinical partner, University Health System.
Read the full story in Impact -
‘Hope in a vial’: COVID-19 vaccinations begin at UT Health San Antonio
UT Health San Antonio was one of only four sites in Texas to receive the first doses of the Pfizer vaccine Dec. 14. The university received 5,850 doses, which gained emergency use authorization Dec. 10 from the U.S. Food and Drug Administration.
Read the article at UT Health San Antonio's Newsroom